Jones JO - Search Results

1

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness.

Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, Schones DE, Frenkel B. Little GH, et al. Among authors: jones jo. Cancer Res. 2014 May 15;74(10):2857-68. doi: 10.1158/0008-5472.CAN-13-2003. Epub 2014 Mar 19. Cancer Res. 2014. PMID: 24648349 Free PMC article.

2

High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.

Vuong W, Tew BY, Little GH, Frenkel B, Jones JO. Vuong W, et al. Among authors: jones jo. J Pharmacol Exp Ther. 2016 Nov;359(2):256-261. doi: 10.1124/jpet.116.234567. Epub 2016 Aug 23. J Pharmacol Exp Ther. 2016. PMID: 27554677

3

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Liang M, Adisetiyo H, Li X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ. Liang M, et al. Among authors: jones jo. PLoS One. 2015 Jul 21;10(7):e0131232. doi: 10.1371/journal.pone.0131232. eCollection 2015. PLoS One. 2015. PMID: 26196517 Free PMC article.

4

Circulating tumor cells in prostate cancer: Does (nuclear) size matter?

Pal SK, Agarwal N, Jones JO. Pal SK, et al. Among authors: jones jo. Cancer. 2015 Sep 15;121(18):3190-2. doi: 10.1002/cncr.29454. Epub 2015 May 14. Cancer. 2015. PMID: 25980931 Free article. No abstract available.

5

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S, Kortylewski M. Hossain DM, et al. Clin Cancer Res. 2015 Aug 15;21(16):3771-82. doi: 10.1158/1078-0432.CCR-14-3145. Epub 2015 May 12. Clin Cancer Res. 2015. PMID: 25967142 Free PMC article.

6

The androgen receptor malignancy shift in prostate cancer.

Copeland BT, Pal SK, Bolton EC, Jones JO. Copeland BT, et al. Among authors: jones jo. Prostate. 2018 May;78(7):521-531. doi: 10.1002/pros.23497. Epub 2018 Feb 23. Prostate. 2018. PMID: 29473182 Review.

7

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO. Pal SK, et al. Among authors: jones jo. Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19. Cancer. 2018. PMID: 29266182 Free article.

8

Androgen Receptor and PI3K Pathway Activity in Ovarian Cancer.

Hill A, Cristea M, He M, Frankel P, Neuhausen S, Pal SK, Jones JO. Hill A, et al. Among authors: jones jo. J Cancer Res Ther Oncol. 2019 Mar;7(1):103. doi: 10.17303/jcrto.2019.7.103. Epub 2019 May 7. J Cancer Res Ther Oncol. 2019. PMID: 34926721 Free PMC article.

9

Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate.

Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Kim W, et al. Among authors: jones jo. Prostate Cancer Prostatic Dis. 2014 Sep;17(3):292-9. doi: 10.1038/pcan.2014.27. Epub 2014 Jul 22. Prostate Cancer Prostatic Dis. 2014. PMID: 25047002

10

Tissue-selective regulation of androgen-responsive genes.

Otto-Duessel M, He M, Jones JO. Otto-Duessel M, et al. Among authors: jones jo. Endocr Res. 2012;37(4):203-15. doi: 10.3109/07435800.2012.668254. Epub 2012 May 16. Endocr Res. 2012. PMID: 22591338 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters